All articles by Robert Barrie

Robert Barrie

Robert Barrie is a trainee reporter for Medical Device Network, covering developments in the healthcare sector. Coming from a scientific and medical background, Robert has reported across various topics with expertise in neuroscience, genetics, and epidemiology. Previously, he worked on a freelance basis with New Scientist.

Micro Medical completes enrollment for stent pivotal trial

The device, which is already CE marked, could join a US vascular stent market expected to reach $2bn by 2033.

BlueSkeye AI to begin trial of AI mental health app for perinatal depression

The app will scan users’ faces and analyse voices to detect and monitor depression in women at different stages of pregnancy.

BiVACOR wins IDE to start first-in-human study for artificial heart

The first-in-human study will evaluate the safety and feasibility of the total artificial heart to bridge the time to a heart transplant.

MHRA approves Ethris’ Phase I trial for inhaled mRNA drug

ETH47 is Ethris’ first candidate to enter clinical trials, with an expected trial initiation date in December 2023.

FDA grants IDE to RTI Surgical for breast reconstruction device trial

The trial, which is expected to commence in the first half of 2024 across US sites, will test the safety and effectiveness of the dermal matrix.

Junshi publishes positive Phase III results for Covid-19 pill VV116

The antiviral tablet, already approved in China in January 2023, significantly reduced the time to sustained clinical symptom resolution.

Eli Lilly supports Alto Neuroscience in $45m Series C round

The funding will go towards the development of Alto Neuroscience’s four CNS candidates, with Phase II study data readouts expected by early 2025.

GRAIL to initiate clinical trial of cancer test in Medicare population

The 50,000-participant US trial joins another study currently underway in England in partnership with the NHS.

Ingestible pill that monitors vitals yields positive results in human trial

Data wirelessly collected from the pill inside the stomach demonstrated it can accurately detect respiration and cardiac rate.

Surmodics reveals two-year data from drug-coated balloon trial

Data after 24 months demonstrated the balloon, which releases the anti-restenotic drug sirolimus, met trial’s primary endpoints.